Channels

 

Special Offers & Promotions

 

 

Latest News

 

 

View Channel

New Products

 

 

View Channel

Video Presentations

 

 

View Channel

Separation Science

 

 

View Channel

Microscopy & Image Analysis

 

 

View Channel

Laboratory Automation & IT Solutions

 

 

View Channel

 

Polyplus-transfection and the National Institute of Health sign a research license agreement for PEI-based transfection technologies

publication date: Mar 6, 2014
 | 
author/source: Image Box Ltd

Polyplus-transfection announces today that it has granted two agencies of the United States National Institutes of Health

Polyplus-Transfection LogoPolyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health (“NIH”) a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases (“NIAID”) and the National Cancer Institute (“NCI”).

The NIAID and the NCI, by entering into this license agreement, become two of Polyplus’ growing number of sub-licensees who have acquired rights to use of PEI-mediated transfection applications for research purposes. The license provides the NIAID and the NCI with freedom to use this globally recognized high performance technology, from Polyplus-transfection, in its research to produce transfected cells, proteins, viruses and antibodies.  

Polyplus-transfection is the worldwide, exclusive licensee to PEI for transfection applications. Transfection with PEI has the advantages of ease of use, high transfection efficiency and excellent viability in the lines of mammalian cells most frequently chosen by scientists working in protein, virus and antibody production. 

“Signing this license agreement between Polyplus and the NIAID and the NCI, two major US research institutes, keeps our technology at the forefront of the battle to understand, treat and prevent cancer, as well as other infectious, immunologic and allergic diseases,” said Mark Bloomfield, CEO of Polyplus-transfection. “PEI-mediated transfection has become a core tool for all researchers working in these fields. The execution of this agreement with the NIH is another demonstration of the strength and significant value of Polyplus’ specific intellectual property rights in PEI-mediated nucleic acid delivery for research purposes.”  

Financial terms were not disclosed.


more about research license


About Polyplus-transfection SA

Polyplus-transfection SA is a biotechnology company that develops, markets and sells innovative solutions for the in vivoin vitro and ex vivo delivery of nucleic acids in research, bioproduction and therapeutics. Located close to the University of Strasbourg in Eastern France, Polyplus-transfection has been ISO 9001-certified since 2002 and supplies its proprietary range of reagents for the transfection of genes, oligonucleotides and siRNA through a worldwide distributor network. Polyplus reagents are involved in a growing number of clinical trials worldwide. In addition, Polyplus-transfection holds a broad estate of patents and licenses including original methods for therapeutic siRNA delivery.


more about Polyplus-Transfection




 

News Channels

 

 

Subscribe to any of our newsletters for the latest on new laboratory products, industry news, case studies and much more!

Newsletters from Lab Bulletin

 

Request your free copies HERE

 

 

 

Popular this Month

Top 10 most popular articles this month

 

 

Today's Picks

 

 

 

 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd.


 

Media Partners

 

Exhibitions & Events